MK-2118
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $4.4M | 159 | 0 |
| 2019 | $3.8M | 213 | 0 |
| 2018 | $1.6M | 142 | 0 |
| 2017 | $50,873 | 19 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.8M | 533 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab or by Subcutaneous Injection in Combination with Pembrolizumab for Patients with Advanced,Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $9.2M | 0 |
| A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab or by Subcutaneous Injection in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $579,446 | 0 |
| A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced,Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $50,873 | 0 |
Top Doctors Receiving Payments for MK-2118
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ny, NY | $9.8M | 533 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $9.8M
- Total Doctors 0
- Transactions 533
About MK-2118
MK-2118 is a drug associated with $9.8M in payments to 0 healthcare providers, recorded across 533 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $4.4M was paid across 159 transactions to 0 doctors.
The most common payment nature for MK-2118 is "Unspecified" ($9.8M, 100.0% of total).
MK-2118 is associated with 3 research studies, including "A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab or by Subcutaneous Injection in Combination with Pembrolizumab for Patients with Advanced,Metastatic Solid Tumors or Lymphomas" ($9.2M).